Sotatercept
Based on 2 publication(s) in Google Scholar
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 1001080-50-7
- Molecular Weight:77.63 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sotatercept
More
Biological Activity
|
ACVR2A |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[Homo sapiens ACVR2A (activin A receptor type 2A, ActR-II, ActRIIA)]2-IGHG1 Fc (Fragment constant)
ELISA, FACS, Functional assay
-
Immobilized Activin A Protein, Human/Mouse/Rat (HEK293, HY-P70311) can bind Sotatercept. The EC50 for this effect is 5.2 ng/mL.
Chemical Information
-
CAS No. 1001080-50-7
-
Appearance Liquid
-
Molecular Weight 77.63 kDa
-
Color Colorless to light yellow
-
SMILES
[Sotatercept]
-
Synonyms
ACE-011; MK-7962
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
bioRxiv
Sotatercept Reverses SIN3a Deficiency-Driven PAH by Reprogramming BMPR2/TGF-β-HIF-1α Signaling Pathways. [Abstract]2026 Feb 3:2026.02.03.703590. PMID: 41676700
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Humbert M, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384(13):1204-1215. [Content Brief]
[2]. Raje N, et al. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010 Oct;12(5):586-97. [Content Brief]
[3]. Abdulkadyrov KM, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014 Jun;165(6):814-23. [Content Brief]
[4]. Sherman ML, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol. 2013 Nov;53(11):1121-30. [Content Brief]
[5]. Iancu-Rubin C, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013 Feb;41(2):155-166.e17. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz